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Prolonged mitochondrial permeability transition pore (MPTP) opening results in mitochondrial energetic
dysfunction, organelle swelling, rupture, and typically a type of necrotic cell death. However, acute opening
of theMPTP has a critical physiologic role in regulatingmitochondrial Ca2+ handling andmetabolism. Despite
the physiological and pathological roles that the MPTP orchestrates, the proteins that comprise the pore it-
self remain an area of ongoing investigation. Here, we will discuss the molecular composition of the MPTP
and its role in regulating cardiac physiology and disease. A better understanding ofMPTP structure and func-
tion will likely suggest novel cardioprotective therapeutic approaches.Introduction
Mitochondria are critical mediators of cellular life through energy
production as well as death through induction of apoptosis and
necrosis. These diametrically opposed functions are especially
relevant in the heart, where mitochondria supply 90% of the
cardiomyocyte’s ATP (Harris and Das, 1991), and cell death
due to mitochondrial intrinsic killing mechanisms underlies a
host of cardiac diseases (Lesnefsky et al., 2001). While many
death pathways converge on mitochondria, there has been an
increasing body of evidence indicating that the mitochondrial
permeability transition pore (MPTP) acts as a key nodal point in
mediating cardiac dysfunction and cell death.
Mitochondrial permeability transition is the phenomenon
whereby the inner membrane suddenly allows free passage of
solutes up to 1.5 kDa in size (Haworth and Hunter, 1979; Hunter
and Haworth, 1979a, 1979b). MPTP opening results in inner
membrane potential collapse, respiratory chain uncoupling,
halt of mitochondrial ATP synthesis, and eventually mitochon-
drial swelling, rupture, and cell death (Halestrap, 2009).
Given the intimate links between the MPTP, mitochondrial
function, and cell death, permeability of the inner membrane is
a critical decision point between cellular life and death. Thus,
the MPTP is an attractive target for cell death prevention in a
host of disease states. Indeed, MPTP inhibition via targeting cy-
clophilin D (CypD), the best-characterized regulator of the
MPTP, produced mice with protection from cell death in an array
of tissues in response to select disease stimuli (Baines et al.,
2005; Martin et al., 2009; Millay et al., 2008; Ramachandran
et al., 2011). However, despite our understanding of the patho-
logical consequences of MPTP opening, the field currently lacks
an understanding of the complete molecular constituents of the
MPTP complex as well as its ultimate physiological role in car-
diac function and metabolism.
The Molecular Identity of the MPTP
The MPTP was initially characterized by Hunter and Haworth
(Haworth and Hunter, 1979; Hunter and Haworth, 1979a,206 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.1979b) as a non-selective channel with a peak conductance of
1.3 nS (Szabo´ and Zoratti, 1992). Pore opening is activated
by Ca2+ together with phosphate and reactive oxygen species
(ROS) and is inhibited by numerous factors including adenine
nucleotides, low pH, divalent cations like Mg2+, and CypD inhib-
itors such as cyclosporine A (CsA) and sanglifehrin A (Halestrap
et al., 2004). MPTP activation may also be subject to additional
layers of regulation through modulation by kinases as well as
post-translational modification of CypD, as previously reviewed
more comprehensively (Elrod and Molkentin, 2013; Vagnozzi
et al., 2012).
While the biophysical properties of the MPTP are well estab-
lished, identification of the molecular constituents of the
MPTP has proven to be a conundrum that remains unresolved.
Historically, biochemical studies originally suggested that the
MPTP was comprised of the voltage-dependent anion channel
(VDAC) in the outer mitochondrial membrane, the adenine nucle-
otide translocator (ANT) in the inner mitochondrial membrane,
and CypD as its regulator in the matrix of the mitochondria
(Crompton et al., 1998) (Figure 1). In the past decade, however,
genetic studies have systematically tested the requirement of
each of these originally proposed components to MPTP struc-
ture and function, resulting in a dramatically different model
(Figure 1). Below we will summarize work on the molecular
identification of the pore to date and highlight evidence for new
candidates that may serve as either direct pore-forming compo-
nents of theMPTP or that simply function as critical regulators as
part of a larger complex.
Cyclophilin D
The mitochondrial matrix petidyl-prolyl cis-trans isomerase
CypD is a genetically verified and undisputed regulator of
MPTP function. CypD’s involvement in MPTP regulation was
discovered through the investigation of the immunosuppressive
drug CsA, which reduces mitochondrial swelling and was later
shown to bind and inhibit CypD activity (Crompton et al., 1988;
Fournier et al., 1987; Halestrap and Davidson, 1990). Definitive
Figure 1. The Molecular Structure of the MPTP
The original paradigm of theMPTP featured VDAC, ANT, and CypD as the core
constituents of the complex (left). Genetic evaluation of putative MPTP com-
ponents has shown that ANT, PiC, and CypD serve as pore regulators, while
the BH3-domain pro-apoptotic proteins Bax/Bak function in the outer mem-
brane to permit mitochondrial swelling and rupture once the inner membrane
complex opens. The F1F0 ATP synthase has been suggested to be a candidate
for the inner membrane pore-forming unit of the MPTP (right). IMM, inner
mitochondrial membrane; OMM, outer mitochondrial membrane; IMS, inter-
membrane space.
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pendent studies by Baines and colleagues, Nakagawa and col-
leagues, and Basso and colleagues where the gene encoding
this protein was ablated in mice. These studies showed that
mitochondria lacking CypD had reduced sensitivity to Ca2+
and oxidative stress-induced MPTP opening. However, at high
levels of Ca2+, permeability transition could still be elicited, sug-
gesting that CypD controls the sensitivity of MPTP opening
(Baines et al., 2005; Basso et al., 2005; Nakagawa et al., 2005).
Indeed, pharmacological inhibition of CypD or deletion of the
gene encoding this protein reduced MPTP opening and subse-
quently reduced cell death in numerous tissues after ischemic
injury and degenerative disease processes (Baines et al., 2005;
Martin et al., 2009; Millay et al., 2008; Ramachandran et al.,
2011; Schinzel et al., 2005; Wissing et al., 2010). However, to
date the precise mechanism whereby CypD controls MPTP
opening has not been determined. Indeed, while CypD can
directly bind a number of mitochondrial inner membrane pro-
teins implicated in affecting permeability transition (see below),
the consequences of these interactions are still not known.
VDAC
The VDAC was first suggested to serve as the outer membrane
component of the MPTP due to the fact that the electrophysio-
logical properties of VDAC were similar to those of the MPTP
and that VDAC functions as a nonselective pore to anions and
cations (Szabo´ et al., 1993; Szabo´ and Zoratti, 1993). The
involvement of VDAC in MPTP formation was further bolstered
by the fact that VDAC, ANT, and CypD could be reconstituted
into proteoliposomes to yield a CsA-sensitive pore (Crompton
et al., 1998). However, genetic studies showed thatmitochondria
lacking all three VDAC isoforms retained an unaltered ability to
undergo permeability transition (Baines et al., 2007), and further,
instead of being protective, loss of VDAC2 expression in cultured
cells potentiated cell death (Baines et al., 2007; Cheng et al.,
2003), collectively suggesting that VDAC is not an essential
component of the MPTP.ANT
The ANT is a 32 kDa inner membrane transporter responsible for
the import of ADP into the mitochondrial matrix in exchange for
ATP and as such is an integral component of the mitochondrial
ATP synthesis machinery (Klingenberg, 2008). ANT was hypoth-
esized to be the inner membrane pore-forming component of the
MPTP given that adenine nucleotides and bongkrekic acid, the
latter being an ANT inhibitor that stabilizes the ‘‘m’’ conformation
of the protein, inhibit MPTP activity while carboxyatractylate, an
ANT effector that promotes the ‘‘c’’ conformation of the protein,
stimulates MPTP opening (Haworth and Hunter, 2000; Klingen-
berg, 1989). Further, ANT is a direct binding partner of CypD
(Crompton et al., 1998; Woodfield et al., 1998), and reconstitu-
tion of ANT alone or in combination with CypD and VDAC into
proteoliposomes yielded pores withMPTP characteristics (Brus-
tovetsky and Klingenberg, 1996; Brustovetsky et al., 2002;
Crompton et al., 1998; Ru¨ck et al., 1998). However, in vivo ge-
netic inactivation of the most abundant ANT isoforms (Ant1
and Ant2 genes) in liver resulted in mitochondria that were still
able to undergo Ca2+ induced permeability transition, although
higher concentrations of Ca2+ were required (Kokoszka et al.,
2004). An additional ANT gene, Ant4, was recently identified in
both humans and mice (Brenner et al., 2011; Dolce et al.,
2005), thus introducing the possibility that ANT ablation in the
liver was incomplete in studies conducted by Kokoszka and
colleagues. However, since murine Ant4 is mainly expressed
in pluripotent stem cells and germ cells, this additional isoform
of ANT might not contribute significantly to the previous MPTP
studies conducted in the liver (Kokoszka et al., 2004). Finally,
there is evidence that ANT may represent a major site of oxidant
stress and thiol modulation of MPTP function (Halestrap et al.,
1997). Collectively, studies on ANT suggest that it is not a
requisite component of the MPTP, but it clearly regulates
MPTP activity.
Phosphate Carrier
The mitochondrial phosphate carrier (PiC) is an inner membrane
solute carrier that is the primary transporter of inorganic phos-
phate (Pi) into the mitochondrial matrix (Kolbe et al., 1984;
Palmieri, 2004). As such, PiC plays a key role in mitochondrial
oxidative phosphorylation (OXPHOS) and energy production as
it supplies mitochondria with the Pi required for ATP synthesis
(Kolbe et al., 1984; Palmieri, 2004). PiC was introduced as a
regulator of cell death and the MPTP because PiC overexpres-
sion in cultured cells induced death (Alcala´ et al., 2008), and Pi
has long been known to facilitate MPTP opening (Al-Nasser
and Crompton, 1986; Beatrice et al., 1980; Crompton and Costi,
1988; Varanyuwatana and Halestrap, 2012). PiC was further pro-
posed to be a candidate for the inner membrane component of
the MPTP because it was also a CypD binding partner (Leung
et al., 2008), and it can form pores in vitro when reconstituted
into liposomes (Schroers et al., 1997). However, the essential na-
ture of PiC’s contribution to MPTP structure and function was
called in to question given the observation that partial reduction
of PiC protein with an siRNA approach resulted in no effect on
MPTP opening (Gutie´rrez-Aguilar et al., 2014; Varanyuwatana
and Halestrap, 2012), suggesting that PiC was not required for
permeability transition. However, cardiomyocyte-specific dele-
tion of the gene encoding PiC protein, which resulted in anCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 207
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ed Ca2+ overload-induced MPTP opening (Kwong et al., 2014).
This attenuation of MPTP opening conferred protection against
cardiac ischemia-reperfusion injury (Kwong et al., 2014). How-
ever, since the MPTP retained full function under phosphate-
free conditions, these findings collectively suggest that the PiC
is not a direct pore component of theMPTP, but instead its ability
to alter matrix Pi levels secondarily impacted pore opening.
F1F0 ATP Synthase
The mitochondrial F1F0 ATP synthase has more recently
emerged as a strong candidate to be the core component of
the MPTP in the inner membrane (Figure 1). The F1F0 ATP
synthase is a multi-subunit enzymatic complex that couples pro-
ton translocation across the inner membrane to ATP synthesis.
The F0 proton-translocating domain of the ATP synthase is
embedded in the inner membrane and is connected to the F1
catalytic domain through the central and peripheral stalks
(Jonckheere et al., 2012). CypD was initially found to modulate
ATP synthase activity by binding to the OSCP subunit of the pe-
ripheral stalk (Giorgio et al., 2009, 2013), and purified dimers of
the F1F0 ATP synthase reconstituted into lipid bilayers recapitu-
lated channel activity similar to that of the MPTP (Giorgio et al.,
2013). Reconstitution of just the purified c subunit ring of the
F0 domain into liposomes could also produce a high-conduc-
tance voltage-gated channel that was sensitive to adenine
nucleotides but not CsA (Alavian et al., 2014). Similarly, reconsti-
tution of complete F1F0 ATP synthase monomers including the
OSCP subunit restored CypD/CsA-regulated channel activity.
Finally, shRNA-mediated reduction of the c subunit prevented
Ca2+-mediated MPTP opening and conferred protection against
Ca2+ overload-induced death in cultured cells and glutamate ex-
citotoxic death in cultured neurons (Alavian et al., 2014; Bonora
et al., 2013). Together, these studies provide compelling evi-
dence that the ATP synthase is required for proper MPTP func-
tion. However, further work is required to reconcile two potential
models: ATP synthase dimers forming the MPTP versus ATP
synthase monomers alongside the c subunit ring forming the
pore (Alavian et al., 2014; Giorgio et al., 2013). Moreover, it
also remains possible that the ATP synthase alters the activity
of an as yet unidentified component that is the actual pore itself.
In vivo genetic loss-of-function analyses of the various ATP syn-
thase components will be helpful in resolving this issue.
Bax/Bak
The pro-death Bcl-2 family member proteins Bax and Bak are
central players in apoptotic cell death. In response to apopto-
genic stimuli, Bax/Bak oligomerize to permeabilize the mito-
chondrial outer membrane, thereby permitting cytochrome c
release and the subsequent steps in mediating apoptosis (Tait
and Green, 2010). In addition to this role in apoptotic cell death,
Bax/Bak have been implicated in MPTP regulation through
their ability to induce a level of outer mitochondrial membrane
permeability that allows MPTP opening to progress to organelle
swelling and eventual rupture (Karch et al., 2013). Indeed, mito-
chondria lacking Bax/Bak are resistant to MPTP opening, and
reconstitution of Bax/Bak-deficient cells with apoptosis/oligo-
merization-impaired Bax mutants restored both MPTP opening
(Karch et al., 2013; Whelan et al., 2012) and outer mitochondrial208 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.membrane permeability (Karch et al., 2013). Moreover, absence
of Bax/Bak is protective against cardiac ischemia-reperfusion
injury (Karch et al., 2013; Whelan et al., 2012) and, combined
with CypD deficiency, did not confer additional protection (Whe-
lan et al., 2012). Prior to this more recent work, Bax and Bak
overexpression were originally shown to regulate MPTP opening
in isolated mitochondria, in a CsA- and bongkrekic acid-depen-
dent manner (Narita et al., 1998). Collectively, these findings
support the hypothesis that Bax/Bak are essential for MPTP to
progress to organelle swelling and rupture at the level of the
outer mitochondrial membrane once the inner membrane com-
ponents of the MPTP are engaged in response to Ca2+ or ROS
stimulation.
TSPO and C1qbp
The translocator protein (TSPO), also known as the peripheral
benzodiazepam receptor, is an outer mitochondrial membrane
protein that was initially suggested to regulate MPTP function
due to the effects of TSPO ligands on MPTP opening (Chelli
et al., 2001; Li et al., 2007; Pastorino et al., 1994). TSPO was
further found to associate with VDAC and ANT, thereby linking
TSPO directly to regulatory components of the MPTP (McEnery
et al., 1992). However, a recent mouse model for the conditional
deletion of TSPO from the liver and heart definitively showed that
this protein does not participate in MPTP regulation (Sileikyt _e
et al., 2014).
C1qbp (complement 1q binding protein) was initially identified
as a plasma membrane receptor for complement 1q that could
also form homotrimeric pores (Jiang et al., 1999) with the ability
to insert within the mitochondrial inner membrane and possibly
be part of the MPTP (Starkov, 2010). Overexpression of C1qbp
in rat fibroblasts induced mitochondrial swelling, dysfunction,
and cell death (Chowdhury et al., 2008). However, analyses of
C1qbp gain- and loss-of-function phenotypes in mouse embry-
onic fibroblasts actually suggested this protein was an inhibitor
of the MPTP (McGee and Baines, 2011). Hence, it is unlikely
that that this protein serves as a direct pore-forming component
of the MPTP.
Physiological Function of the MPTP in Metabolism
Mitochondria are central to cellular metabolism and energy pro-
duction. With genetic studies confirming ANT (Kokoszka et al.,
2004) and PiC (Kwong et al., 2014) as MPTP regulators and the
F1F0 ATP synthase as a candidate for the pore-forming compo-
nent itself (Alavian et al., 2014; Giorgio et al., 2013), there ap-
pears to be a connection between the MPTP and mitochondrial
energy metabolism (Figure 2). The F1F0 ATP synthase, ANT, and
PiC are not only functionally coupled for mitochondrial ATP pro-
duction, but physically coupled into an inner membrane super-
complex termed the ATP synthasome (Ko et al., 2003). Loss of
any one of the ATP synthasome components results in impaired
mitochondrial oxidative phosphorylation (Bakker et al., 1993;
Graham et al., 1997) and energy production (Kwong et al.,
2014; Tatuch and Robinson, 1993). Indeed, mice lacking either
PiC or ANT1 protein in the heart develop a severe mitochondrial
cardiomyopathy characterized by hypertrophy, ventricular dila-
tion, cardiac dysfunction, and mitochondrial hyperproliferation
(Graham et al., 1997; Kwong et al., 2014; Narula et al., 2011).
Human patients with mutations in the skeletal muscle isoform
Figure 2. Physiological and Pathophysiological Roles of theMPTP in
the Heart
Transient opening of the MPTP is implicated in ROS signaling, cardiomyocyte
development, and mitochondrial Ca2+ efflux that affects metabolism. Key
components of the MPTP (PiC, ANT, and the F1F0 ATP synthase) comprise the
ATP synthasome, thereby providing a direct link to mitochondrial energy
metabolism. Prolonged MPTP opening leads to loss of mitochondrial mem-
brane potential, cessation of ATP synthesis, mitochondrial swelling, rupture,
and death. Unregulated MPTP opening has been found to contribute to
cardiac ischemia-reperfusion injury and the development of heart failure. Dc,
inner membrane potential.
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cardiomyopathy, and shortened lifespan (Mayr et al., 2007,
2011). Similarly, patients with ANT1 protein deficiency can
present with hypertrophic cardiomyopathy, muscle myopathy,
lactic acidosis, and exercise intolerance (Bakker et al., 1993;
Palmieri et al., 2005). Finally, mutations in the mitochondrial
MT-ATP8 gene are associated with hypertrophic cardiomyopa-
thy (Jonckheere et al., 2010; Ware et al., 2009).
In further support of the MPTP being linked to metabolism,
mice lacking CypD protein showed increased activity of two
key matrix dehydrogenases of the tricarboxylic acid cycle (pyru-
vate dehydrogenase and a-ketoglutarate dehydrogenase) (Elrod
et al., 2010). Moreover, in-depth proteomic analyses of these
CypD-deficient mice revealed alterations in enzymes involved in
pyruvate and branched-chain amino acid metabolism, as well
as the Kreb’s cycle (Menazza et al., 2013), suggesting that
MPTP desensitization produces global reprogramming of cellular
metabolism. Taken together, these studies suggest that the
MPTP may be a nodal point of cell life and death decisions by
integrating energy metabolism with the cell death machinery.
MPTP in Ca2+ Efflux
In addition to energy production, mitochondria are major sites
of intracellular Ca2+ signaling and accumulation (Figure 2).
Increased Ca2+ content in the mitochondrial matrix directly en-
hances metabolic output by increasing the activity of tricarbox-
ylic acid cycle dehydrogenases and the ATP synthase (Balaban,
2009; Hansford and Zorov, 1998). However, sustained mito-
chondrial matrix Ca2+ overload triggers prolonged high-conduc-
tance MPTP opening, leading to mitochondrial dysfunction and
cell death (see below). Thus, maintenance of mitochondrial
Ca2+ homeostasis is of critical importance. Mitochondrial Ca2+
influx is controlled by the mitochondrial calcium uniporter
(MCU) (Baughman et al., 2011; De Stefani et al., 2011), whileefflux is controlled by the mitochondrial Na+/Ca2+ exchanger
(NCLX) (Palty et al., 2010) and the mitochondrial H+/Ca2+
exchanger (Jiang et al., 2009; Tsai et al., 2014). Transient or
low-conductance opening of the MPTP has also been proposed
to serve as an additional mode of Ca2+ efflux that mitigates sus-
tained matrix Ca2+ overload (Bernardi and von Stockum, 2012;
Ichas and Mazat, 1998). In support of this hypothesis, both iso-
lated mitochondria from CypD-deficient mice and intact cardio-
myocytes treated with CsA display elevated matrix Ca2+ levels
(Elrod et al., 2010). Additionally, transient asynchronous MPTP
opening can allow for temporary membrane potential depolari-
zation in limited populations of mitochondria while the vast ma-
jority of the mitochondria remain polarized and functional (Korge
et al., 2011). In contrast to these studies, mitochondrial Ca2+
efflux rates measured in intact HeLa cells were completely unaf-
fected by MPTP inhibition either by CsA or by siRNA-mediated
reduction of the ATP synthase c subunit (De Marchi et al.,
2014), suggesting that the MPTP may not play a role in Ca2+
efflux under all ex vivo assay conditions. Thus, the MPTP’s
participation in mitochondrial Ca2+ efflux under specific condi-
tions or in certain cellular contexts needs further investigation.
MPTP in ROS Signaling
In addition to Ca2+ efflux, transient opening of the MPTP has
been linked to mitochondrial ROS signaling (Zorov et al., 2000).
Mitochondria are a major source of cellular ROS production,
and although excessive ROS can contribute to accelerated
aging and cell death, physiological levels of ROS can underlie
processes ranging from ion channel homeostasis to gene
expression (Figure 2). Through the use of a novel genetically en-
coded mitochondrial sensor, mt-cp-YFP (a matrix-targeted,
circularly permuted yellow fluorescent protein), it has been sug-
gested that mitochondria from resting adult cardiomyocytes (Li
et al., 2012; Wang et al., 2008) or Langendoff perfused hearts
(Wang et al., 2008) can release discrete bursts or ‘‘flashes’’ of
superoxide. The MPTP was implicated in cardiac mitochondrial
superoxide flash production as flashes were coincident with
transient decreases in mitochondrial membrane potential (Li
et al., 2012; Wang et al., 2008), and MPTP inhibition with bongk-
rekic acid, CsA, or by CypD knockdown greatly decreased flash
frequency (Wang et al., 2008). It should be noted, however, that
the MPTP’s role in superoxide flashes may be tissue specific as
neither CsA inhibition (Pouvreau, 2010) nor CypD protein loss
(Wei et al., 2011) had an effect on flash frequency in skeletal mus-
cle fibers. It also must be noted that instead of superoxide pro-
duction, mt-cp-YFP flashes were suggested to reflect transient
alkalinization of the matrix (Schwarzla¨nder et al., 2012). While
the precise nature of flashes is still not fully understood, they
are linked to metabolic activity (Fang et al., 2011) and mitochon-
drial function (Wang et al., 2008), and there is increased inci-
dence of flashes during the re-oxygenation phase of cardiac
ischemia-reperfusion injury (Wang et al., 2008).
MPTP in Cardiac Development
The MPTP has also been suggested to play a novel role in cardi-
omyocyte development and mitochondrial maturation (Figure 2).
Work by Horn and colleagues showed that during murine embry-
onic development, cardiac mitochondria underwent a pro-
found structural and functional maturation that tracked withCell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc. 209
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from immature E9.5 myocytes were fragmented with disorga-
nized cristae, depressed mitochondrial membrane potential,
and elevated ROS production, suggesting that the MPTP adop-
ted an open conformation. However, by E13.5, the mitochondria
were organized into tubular networks with defined cristae struc-
ture, higher membrane potential, and decreased ROS, suggest-
ing that the MPTP was closed. In support of this hypothesis,
MPTP inhibition by CsA or by CypD protein loss, as well as
administration of ROS scavengers resulted in E9.5 myocytes
displaying more mature myofibrillar organization and more
developed mitochondrial networks (Hom et al., 2011).
Pathophysiological Roles of the MPTP in Cell Death
A critical step in the activation of cell death programs, either
apoptotic or necrotic, is mitochondrial membrane permeabiliza-
tion (Kroemer et al., 2007). However, the mode whereby mito-
chondrial membranes are disrupted may be the deciding factor
as to which death program the cell engages. In the classical
mitochondrial apoptotic pathway (as previously reviewed more
comprehensively by Spierings et al., 2005 and Tait and Green,
2010), outer membrane permeabilization by the pro-death Bcl-
2 family member proteins Bax and Bak allows for apoptogenic
factors like cytochrome c, Smac/DIABLO, and AIF to be released
from the intermembrane space into the cytosol, leading to cell
death by apoptosis. In contrast, stimuli such as Ca2+ overload
or ROS cause MPTP opening leading to mitochondrial inner
membrane permeabilization, membrane potential dissipation,
impaired respiratory chain function, halt of mitochondrial ATP
synthesis, organelle swelling, and outer membrane rupture.
This ultimately results in necrotic cell death, characterized by
loss of plasma membrane integrity and cell rupture (Golstein
and Kroemer, 2007).
Certainly, there is considerable crosstalk between mitochon-
drial apoptotic and necrotic pathways as Bax/Bak participate
in both apoptosis and necrosis at the level of the outer mitochon-
drial membrane (Karch et al., 2013; Wei et al., 2001; Whelan
et al., 2012). However, while both apoptotic and necrotic path-
ways can contribute to cardiomyocyte loss in disease, the
MPTP-necrosis pathway is distinct from apoptosis, as cells
lacking CypD are protected against stimuli that induce MPTP
opening (like Ca2+ and ROS overload) but retain sensitivity to
apoptosis-inducing agents (Baines et al., 2005; Nakagawa
et al., 2005). Bax/Bak-deficient cells are resistant to both forms
of death, and re-introduction of Bax mutants that are unable to
oligomerize in the outer membrane to generate large apoptotic
pore can still increase the ‘‘micropermeability’’ of the outermem-
brane to facilitate regulated necrosis and organelle swelling once
the inner membrane of the MPTP is opened (Karch et al., 2013).
Ischemia-Reperfusion Injury
During myocardial ischemia, oxygen deprivation arrests mito-
chondrial respiratory chain function and ATP synthesis, causing
a marked drop in cardiac ATP content (Jennings and Reimer,
1991). This impaired mitochondrial metabolic flux forces pyru-
vate to be metabolized into lactic acid, leading to a drop in
cellular pH and metabolic acidosis (Figure 2). To re-establish
cytosolic pH and ionic balance, the plasma membrane Na+/H+
exchanger is activated to extrude H+ and the Na+/K+ ATPase is210 Cell Metabolism 21, February 3, 2015 ª2015 Elsevier Inc.engaged to remove excess cytosolic Na+. Because cellular
ATP is constrained, Na+/K+ ATPase activity is blunted, leading
to a progressive rise in Na+, which secondarily triggers the
Na+/Ca2+ exchanger to extrude Na+ in exchange for Ca2+ influx.
Moreover, because the major cellular Ca2+ pumping mecha-
nisms require ATP, and the MPTP remains open as ATP levels
dissipate, Ca2+ levels in the ischemic heart are further elevated.
In addition to this Ca2+ elevation, ROS production is also
increased in the ischemic heart (Murphy and Steenbergen,
2008). Thus, the ischemic heart is primed for prolonged MPTP
opening that leads to cardiomyocyte death (Murphy and Steen-
bergen, 2008).
In light of the fact that theMPTP is open during reperfusion and
that the MPTP has been proposed to contribute significantly to
reperfusion-mediated cardiac damage (Griffiths and Halestrap,
1995), the MPTP is a prime target for therapies aimed at miti-
gating cell loss. Indeed, in genetic in vivo proof-of-concept
studies, inhibition of MPTP opening by deletion of MPTP compo-
nents, notably the genes encoding CypD (Baines et al., 2005;
Nakayama et al., 2007), PiC (Kwong et al., 2014), and Bax/
Bak (Karch et al., 2013; Whelan et al., 2012), reduced cardiac
damage sustained in response to ischemia-reperfusion injury.
Administration of the CypD inhibitors sanglifehrin A (Clarke
et al., 2002; Lim et al., 2007) or CsA (Griffiths and Halestrap,
1993, 1995; Lim et al., 2007) reduced ischemic death and
improved functional recovery in both ex vivo and in vivo models
of cardiac ischemia-reperfusion injury. Similarly, non-immuno-
suppressive analogs of CypD such as [MeAla6]-cyclosporine
(Griffiths and Halestrap, 1995), Debio-025 (Gomez et al., 2007),
and NIM811 (Argaud et al., 2005) were strongly cardioprotective,
further confirming the MPTP as a target for therapy. Importantly,
a pilot clinical trial in patients presenting with myocardial infarc-
tion showed CsA infusion at the time blood flow was restored
reduced infarct size by 40% compared to placebo (Piot et al.,
2008). In a subsequent follow-up study with the same group
of patients, the reduction in infarct size from the single dose
of CsA was maintained 6 months post-treatment, and such pa-
tients displayed attenuated left ventricular remodeling with
improved ventricular function (Mewton et al., 2010).
Finally, there is evidence that mitochondrial association of the
glycolytic enzyme hexokinase II can confer protection against
cell death and reduce the extent of ischemic injury in the heart,
possibly by limiting outer mitochondrial membrane permeabili-
zation, cytochrome c release, and oxidative stress, thus second-
arily constraining MPTP activation (Halestrap et al., 2014).
Clearly, MPTP inhibition holds therapeutic promise for myocar-
dial infarction-based injury, and as the molecular makeup of
the MPTP becomes clearer, it will be important to explore phar-
macological targeting of new pore components.
Heart Failure
Heart failure is associatedwith cumulative attrition of cardiomyo-
cytes in cardiac disorders ranging fromhypertension toMI.While
a multitude of factors can contribute to pump dysfunction, key
characteristics of failing cardiomyocytes include: dysregulation
of Ca2+ homeostasis (Luo and Anderson, 2013), ATP insuffi-
ciency (Ingwall, 2009), and increased oxidative stress (Keith
et al., 1998). Since these are conditions that favor MPTP open-
ing, it has been hypothesized that the MPTP could be a point
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due to necrosis. In support of this concept, mice with cardiomy-
opathy due to Ca2+ overload mediated by overexpression of the
b2a subunit of the L-type Ca2+ channel were protected by loss of
the gene encoding CypD (Nakayama et al., 2007). In addition,
CypD-deficient mice subjected to prolonged MI displayed
reduced mortality and decreased infarct size (Lim et al., 2011),
suggesting that MPTP inhibition could be beneficial.
In contrast, CypD-deficient mice displayed accelerated car-
diac disease in response to a surgical model of chronic pressure
overload as well as increased hypertrophy and mortality in
response to forced exercise (Elrod et al., 2010), which are likely
due to metabolic deficiencies in the mitochondria lacking
CypD, as discussed earlier. Further, loss of CypD exacerbated
the heart failure phenotype observed in the Ca2+/calmodulin-
dependent protein kinase IId-c model of cardiomyopathy,
indicating maladaptive consequences of prolonged MPTP
desensitization (Elrod et al., 2010). In line with these findings,
as mentioned above, long-term cardiac loss of the MPTP regu-
lators ANT1 and PiC in both mice and humans causes mitochon-
drial cardiomyopathy characterized by mitochondrial structural
abnormalities, cardiac hypertrophy, and ventricular dysfunction,
which again are likely reflective of a metabolic effect (Bakker
et al., 1993; Graham et al., 1997; Kwong et al., 2014; Mayr
et al., 2007; Narula et al., 2011; Palmieri et al., 2005).Future Perspectives
In the past decade, the historical paradigm of MPTP structure
has now given way to a new model that features CypD, ANT,
PiC, Bax/Bak, and the ATP synthase in new roles. The MPTP re-
mains a promising target for cell death prevention and cardiopro-
tection. In particular, CypD inhibitors show promise in making
the transition from bench to bedside as an approach to prevent
cardiomyocyte loss following acute cardiac ischemic damage.
Moving forward, it will be highly desirable to target additional
constituents of the MPTP to provide greater inhibitory ability
than is typically observed with cyclophilin inhibitors like CsA,
which only desensitize the pore. For example, the therapeutic
potential of indirect MPTP regulators such as hexokinase II could
be further developed. Finally, there is an emerging theme that
while central to cell death regulation, the MPTP is equally impor-
tant in regulating cellular metabolism, as many MPTP constitu-
ents, namely the ATP synthase, ANT, and PiC, have primary roles
in mitochondrial energy production. Further insight into how
the MPTP contributes to cardiac physiology is needed as we
consider other cardiac diseases where metabolism is more cen-
trally involved, especially if we want to inhibit the MPTP long-
term, such as in heart failure. Thus, understanding the interface
between the physiological and pathophysiological roles of the
MPTP will be important when employing current MPTP inhibiting
agents or in developing new means of desensitizing or inhibiting
MPTP opening in treating both acute post-ischemic tissue dam-
age and long-term cardiomyocyte dropout in heart failure.ACKNOWLEDGMENTS
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